77 results about "Tetralones" patented technology

The present invention discloses a montelukast sodium preparation technology and intermediates; 7-chloro-2-methylquinine and 3-bromobenzaldehyde are used as raw materials for condensation reaction to obtain a compound A2; by carbon-carbon coupling of the compound A2 and 1-tetralone in the presence of a catalyst, an intermediate compound A3 is obtained; an important intermediate compound A4 is obtained by bio-enzyme catalyzed asymmetric Baeyer-villiger reaction, a chiral center is highly selectively constructed, an important intermediate compound A5 is prepared from the compound A4 by grignard reaction by use of methylmagnesium chloride, finally montelukast sodium (A6) is obtained; according to the technology, the highly chiral important intermediate compound A4 is obtained by bio-enzyme catalyzed asymmetric reaction, the catalyst can be effectively repeatedly used, and the kind of used solvents is less, and the montelukast sodium preparation technology has the characteristics of safety and environmental protection, greatly saves the production cycle, is low in production cost, high in total yield, and simple in operation of production units, and is suitable for industrialized production.

The present invention provides novel 5-substituted tetralones of Formulas I, II, III, and IV and pharmaceutically acceptable salts, esters, amides, and prodrugs thereof, which are useful for treating and preventing uncontrolled or abnormal proliferation of tissues, such as cancer, atherosclerosis, restenosis, and psoriasis. Specifically, the present invention relates to compounds that inhibit the farnesyl transferase enzyme

A process for preparing indanylamine and aminotetralin derivatives from indanone or tetralone oximes by acylating the oximes with an organic anhydride, followed by catalytic hydrogenation in the presence of an organic anhydride with subsequent hydrolysis is described. The process is commercially feasible providing indanylamine and aminotetralin derivatives in high yield that are useful as intermediates in the production of therapeutically active compounds. Also described are novel intermediates, 1-indanone O-acetyl oximes and 1-tetralone O-acetyl oximes.

The invention discloses a preparation method of 3-bromo-1,3,4,5-tetrahydro-2H-benzazepine-2-keto. The preparation method comprises the following stages: alpha-tetralone preparation stage, 2-bromo-3,4-dihydro-N-hydroxy-(2H)-naphthalimide preparation stage and 3-bromo-1,3,4,5-tetrahydro-2H-1-benzazepine-2-keto, wherein the alpha-tetralone preparation stage comprises the following steps: after mixing gamma-butyrolactone, benzene and aluminum chloride anhydrous, raising the temperature to be 60-90 DEG C, and preserving the temperature for reaction for 5-30 hours; after the reaction is finished, performing hydrolysis, layering and washing on 25 parts of 6% hydrochloric acid solution until neutral; and then distilling to remove excessive benzene, and performing high vacuum rectification to obtain alpha-tetralone. Then, the finished product is finally prepared through a bromination reaction, an oximation reaction and a beckmann rearrangement reaction, the purity of the finished product is high, and the yield is as high as more than 90%. Moreover, the production technology is simple, the production cost is low, and the pollution is little.